NB3 Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Neurocrine Biosciences Inc

Watchlist Manager

Watchlist

Price: 120.65 EUR Market Closed

Market Cap: €7.3B

N	Neurocrine Biosciences Inc XBER:NB3	US
K	Kone Oyj DUS:KC4	FI
	eHealth Inc NASDAQ:EHTH	US
	Banque Cantonale Vaudoise OTC:BQCNF	CH
V	Vuzix Corp F:V7XN	US
	Kairos Minerals Ltd ASX:KAIDB	AU
K	Konami Holdings Corp XBER:KOA	JP
	South32 Ltd ASX:S32	AU
V	voestalpine AG XHAM:VAS	AT
B	Barito Renewables Energy PT Tbk IDX:BREN	ID
	Capricor Therapeutics Inc NASDAQ:CAPR	US
L	Legrand SA XBER:LRC	FR

Profitability Summary

Neurocrine Biosciences Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

98%

Strong 3Y Average Gross Margin

98%

Gross Margin is Increasing

98% > 98%

Healthy Operating Margin

26%

Sustainable 3Y Average Operating Margin

22%

Operating Margin is Increasing

18% > 26%

Healthy Net Margin

22%

Sustainable 3Y Average Net Margin

15%

Net Margin is Increasing

11% > 22%

Exceptional Free Cash Flow Margin

27%

Strong 3Y Average Free Cash Flow Margin

23%

Free Cash Flow Margin is Increasing

17% > 27%

Positive ROE

23%

Positive 3Y Average ROE

Positive 3Y Average ROIC

22%

ROIC is Increasing

19% > 20%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.